Ciprofloxacin-BSA Conjugate ML

Ciprofloxacin-BSA Conjugate ML

Catalog Number:
BRAK515984CEL
Mfr. No.:
CM52135-1MG; CM52135-5MG
Price:
$857
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Ciprofloxacin, commonly referred to as Cipro or CIP, is a fluoroquinolone type antibiotic. Today, ciprofloxacin is often prescribed as a last resort for infections with antibiotic resistance or mixed infections. Ciprofloxacin works by inhibiting enzymes that are necessary for bacterial DNA replication. Research has also shown that ciprofloxacin may have some anti-proliferative/apoptotic effects in certain forms of cancer. This ciprofloxacin-BSA conjugate is a medium loading (ML) conjugate with an average of 5 to 10 ciprofloxacin molecules per BSA and can be used for immunization or immunoassay development. Ciprofloxacin is conjugated to BSA via its surface amines. The final conjugate is supplied as a frozen solution in phosphate buffered saline (PBS) and is ready to use after defrosting.

          The product is sold as either 1 vial of 1 mg (Cat# CM52135-1MG) or 5 vials of 1 mg (Cat# CM52135-5MG). For bulk orders, please contact us for a quote.

          Key Features
          • Frozen solution in PBS buffer ready to use after defrosting.
          • Medium loading conjugate with an average 5 to 10 ciprofloxacin molecules per BSA.
          • Concentration accurately determined by UV/HPLC analysis.

          Please contact us at for specific academic pricing.

      • Properties
        • * For Research Use Only. Not for Use in Diagnostic Procedures.

      • Applications
        • Application Description
          • Assay development for detection of ciprofloxacin contaminants
          • Antibody discovery via immunization and hapten recognition
          • Indirect and competitive ELISA assay
      • Reference
        • Mihoko K. al. Development of enrofloxacin ELISA using a monoclonal antibody tolerating an organic solvent with broad cross-reactivity to other newquinolones, Food and Agricultural Immunology, 2007, 18:3-4, 179-187, DOI: 10.1080/09540100701763365
          Li, Y. al. Production of new class-specific polyclonal antibody for determination of fluoroquinolones antibiotics by indirect competitive ELISA, Food and Agricultural Immunology, 2008, 19:4,251-264, DOI: 10.1080/09540100802471538
          Sharma, P. C. al. Ciprofloxacin: review on developments in synthetic, analytical, and medicinal aspects, Journal of Enzyme Inhibition and Medicinal Chemistry, 2010, 25:4, 577-589, DOI: 10.3109/14756360903373350.

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.